Skip to main content
SpringerLink
Log in

Informative combination of CLU rs11136000, serum HDL levels, diabetes, and age as a new piece of puzzle-picture of predictive medicine for cognitive disorders

  • Original Article
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Clusterin (CLU) is the third most important associated risk gene in cognitive disorders. Regarding the controversy about the association of CLU rs11136000 with mild cognitive impairment (MCI), the aim of this study was to investigate a putative association of CLU rs11136000 with MCI as well as the serum biological factors with a special attention to the age as a main dimension of a multifactorial elderly disease in an Iranian elderly cohort in which the mentioned association was not previously investigated. The study also checked the association between diabetes and MCI in this population. A population of 418 individuals containing 236 MCI and 192 control subjects was recruited from the Amirkola health and aging population cohort. Serum biological indexes were assessed by biochemical and enzyme-linked immunosorbent assay, and rs11136000 genotyping was performed using polymerase chain reaction-restriction fragment length polymorphism. Bioinformatics analyses were used to identify the putative effect of rs11136000 on the secondary structure of RNA and chromatin location in different cell lines and tissues. Type 2 diabetes was present with a higher proportion in the MCI group in comparison with the control group (P = 0.041). The frequency of the C allele of CLU rs11136000 was significantly different between cases and controls and was associated with MCI risk (OR 1.79, P = 0.019). Under a dominant genetic model, the CC genotype showed a predisposing effect in individuals aged ≥ 75 years (OR 3.33, P = 0.0004). Interestingly, under an over-dominant model, the CT genotype had a protective effect in this population (OR 4.52, P = < 0.0001). We also found a significant association between the genotypes and high-density lipoprotein (HDL) levels in MCI patients (P = 0.0004). Bioinformatics analysis showed that rs11136000 is located in the transcribed region without any regulatory features such as being enhancer or insulator. Also, the T>C transition of CLU rs11136000 could not cause significant mRNA folding (P = 0.950). Contrary to other studies on Asian populations, this study demonstrated an association between rs11136000 and MCI in an elderly Iranian population. This study also suggests that an age-dependent approach to the previous studies may be performed in order to revise the previous belief in this geographical area. The rs11136000 genotypes in combination with HDL levels and knowledge about diabetes background may be used as a predictive medicine tool for cognitive disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Mariani E, Monastero R, Mecocci P (2007) Mild cognitive impairment: a systematic review. J Alzheimers Dis 12(1):23–35

    Article  Google Scholar 

  2. Jaul E, Barron J (2017) Age-related diseases and clinical and public health implications for the 85 years old and over population. Front Public Health 5:335

    Article  Google Scholar 

  3. Chentli F, Azzoug S, Mahgoun S (2015) Diabetes mellitus in elderly. Indian J Endocrinol Metab 19(6):744–752

    Article  CAS  Google Scholar 

  4. Cukierman T, Gerstein H, Williamson J (2005) Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies. Diabetologia 48(12):2460–2469

    Article  CAS  Google Scholar 

  5. Cheng G et al (2012) Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J 42(5):484–491

    Article  CAS  Google Scholar 

  6. de Silva HV et al (1990) Apolipoprotein J: structure and tissue distribution. Biochemistry 29(22):5380–5389

    Article  Google Scholar 

  7. Thambisetty M et al (2012) Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Neuroimage 59(1):212–217

    Article  CAS  Google Scholar 

  8. Thambisetty M et al (2013) Alzheimer risk variant CLU and brain function during aging. Biol Psychiatr 73(5):399–405

    Article  Google Scholar 

  9. Thambisetty M et al (2010) Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatr 67(7):739–748

    Article  Google Scholar 

  10. Park S, Mathis K, Lee I (2014) The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases. Rev Endocr Metab Disord 15(1):45–53

    Article  CAS  Google Scholar 

  11. Haase CL et al (2015) HDL cholesterol and risk of type 2 diabetes: a mendelian randomization study. Diabetes 64(9):3328–3333

    Article  CAS  Google Scholar 

  12. Park S, Mathis KW, Lee IK (2014) The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases. Rev Endocr Metab Disord 15(1):45–53

    Article  CAS  Google Scholar 

  13. Bertram L, Tanzi RE (2009) Genome-wide association studies in Alzheimer’s disease. Human Mol Genet 18(R2):R137–R145

    Article  CAS  Google Scholar 

  14. Carrasquillo MM et al (2010) Replication of CLU, CR1, and PICALM associations with Alzheimer disease. Arch Neurol 67(8):961–964

    Article  Google Scholar 

  15. Corneveaux JJ et al (2010) Association of CR1, CLU and PICALM with Alzheimer’s disease in a cohort of clinically characterized and neuropathologically verified individuals. Human Mol Genet 19(16):3295–3301

    Article  CAS  Google Scholar 

  16. Harold D et al (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet 41(10):1088–1093

    Article  CAS  Google Scholar 

  17. Lancaster TM et al (2015) Alzheimer’s disease risk variant in CLU is associated with neural inefficiency in healthy individuals. Alzheimer’s Dement 11(10):1144–1152

    Article  Google Scholar 

  18. Bertram L et al (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39(1):17

    Article  CAS  Google Scholar 

  19. Gu H et al (2011) Association of clusterin gene polymorphisms with late-onset Alzheimer’s disease. Dementia Geriatr Cognit Disord 32(3):198–201

    Article  CAS  Google Scholar 

  20. Han Z et al (2018) Analyzing 74,248 samples confirms the association between clu rs11136000 polymorphism and Alzheimer’s disease in caucasian but not Chinese population. Sci Rep 8(1):11062

    Article  Google Scholar 

  21. Jen MY, Gossman WG (2018) Predictive medicine. StatPearls, Orlando

    Google Scholar 

  22. Hosseini SR et al (2014) Cohort profile: the Amirkola health and ageing project (AHAP). Int J Epidemiol 43(5):1393–1400

    Article  Google Scholar 

  23. Ansari NN et al (2010) Validation of a mini-mental state examination (MMSE) for the Persian population: a pilot study. Appl Neuropsychol 17(3):190–195

    Article  Google Scholar 

  24. Ernst J, Kellis M (2012) ChromHMM: automating chromatin-state discovery and characterization. Nat Methods 9(3):215–216

    Article  CAS  Google Scholar 

  25. Gonzalez JR et al (2007) SNPassoc: an R package to perform whole genome association studies. Bioinformatics 23(5):644–645

    Article  Google Scholar 

  26. Allen M et al (2012) Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology 79(3):221–228

    Article  CAS  Google Scholar 

  27. Rizzuto D et al (2012) Dementia after age 75: survival in different severity stages and years of life lost. Curr Alzheimer Res 9(7):795–800

    Article  CAS  Google Scholar 

  28. Grundman M et al (2004) Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 61(1):59–66

    Article  Google Scholar 

  29. Daimon M et al (2011) Association of the clusterin gene polymorphisms with type 2 diabetes mellitus. Metabolism 60(6):815–822

    Article  CAS  Google Scholar 

  30. Han BH et al (2001) Clusterin contributes to caspase-3-independent brain injury following neonatal hypoxia-ischemia. Nat Med 7(3):338–343

    Article  CAS  Google Scholar 

  31. Leskov KS et al (2003) Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 278(13):11590–11600

    Article  CAS  Google Scholar 

  32. Saedi E et al (2016) Diabetes mellitus and cognitive impairments. World J Diabetes 7(17):412–422

    Article  Google Scholar 

  33. Kodl CT, Seaquist ER (2008) Cognitive dysfunction and diabetes mellitus. Endocr Rev 29(4):494–511

    Article  CAS  Google Scholar 

  34. Munshi MN (2017) Cognitive dysfunction in older adults with diabetes: what a clinician needs to know. Diabetes Care 40(4):461–467

    Article  Google Scholar 

  35. Abbatecola AM et al (2006) Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 67(2):235–240

    Article  CAS  Google Scholar 

  36. Bertram L, Tanzi RE (2009) Genome-wide association studies in Alzheimer’s disease. Hum Mol Genet 18(R2):R137–R145

    Article  CAS  Google Scholar 

  37. Cai R et al (2016) Plasma clusterin and the CLU gene rs11136000 variant are associated with mild cognitive impairment in type 2 diabetic patients. Front Aging Neurosci 8:179

    Article  Google Scholar 

  38. Tan L et al (2016) Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer’s disease cohorts. Sci Rep 6:26027

    Article  CAS  Google Scholar 

  39. Morgantini C et al (2011) Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes 60(10):2617–2623

    Article  CAS  Google Scholar 

  40. Gordon SM et al (2011) High density lipoprotein: it’s not just about lipid transport anymore. Trends Endocrinol Metab 22(1):9–15

    Article  CAS  Google Scholar 

  41. Drew BG et al (2009) High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 119(15):2103–2111

    Article  CAS  Google Scholar 

  42. Brunham LR et al (2007) Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 13(3):340–347

    Article  CAS  Google Scholar 

  43. Han R et al (2007) Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism. Diabetologia 50(9):1960–1968

    Article  CAS  Google Scholar 

  44. Rojano E et al (2018) Regulatory variants: from detection to predicting impact. Brief Bioinform. https://doi.org/10.1093/bib/bby039

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge all participants of this study. The present study was supported by a Grant No. 9339436 of Babol University of Medical Sciences, Babol, Iran.

Author information

Author notes

  1. Mohsen Aghajanpour-Mir and Fatemeh Amjadi-Moheb have contributed equally to this work.

Authors and Affiliations

  1. Department of Genetics, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran

    Mohsen Aghajanpour-Mir, Fatemeh Amjadi-Moheb, Tahereh Dadkhah, Elham Ghadami & Haleh Akhavan-Niaki

  2. Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    Mohsen Aghajanpour-Mir

  3. Social Determinants of Health (SDH) Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran

    Seyed Reza Hosseini

  4. Student Research Committee, Babol University of Medical Sciences, Babol, Iran

    Ehsan Assadollahi

  5. Mobility Impairment Research Center, Babol University of Medical Sciences, University of Medical Sciences, Babol, 4717641367, Iran

    Alijan Ahmadi Ahangar

Authors
  1. Mohsen Aghajanpour-Mir
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fatemeh Amjadi-Moheb
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tahereh Dadkhah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seyed Reza Hosseini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elham Ghadami
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ehsan Assadollahi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Haleh Akhavan-Niaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alijan Ahmadi Ahangar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alijan Ahmadi Ahangar.

Ethics declarations

Conflict of interest

Authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aghajanpour-Mir, M., Amjadi-Moheb, F., Dadkhah, T. et al. Informative combination of CLU rs11136000, serum HDL levels, diabetes, and age as a new piece of puzzle-picture of predictive medicine for cognitive disorders. Mol Biol Rep 46, 1033–1041 (2019). https://doi.org/10.1007/s11033-018-4561-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-018-4561-5

Keywords

Search

Navigation